Huons 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases   1 Product   0 Trials   25 News 
  • ||||||||||  Vasforda (bevacizumab biosimilar) / Hanwha Solutions, Prestige BioPharma, Huons, Intas
    Trial completion date, Trial primary completion date, Metastases:  A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin (clinicaltrials.gov) -  Nov 18, 2024   
    P3,  N=650, Active, not recruiting, 
    Trial completion date: Jul 2024 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Jul 2024
  • ||||||||||  Liztox (botulinum toxin type A) / Huons
    Enrollment closed, Trial primary completion date:  To Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy (clinicaltrials.gov) -  Sep 26, 2024   
    P3,  N=188, Active, not recruiting, 
    Trial completion date: Jul 2024 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Jul 2024 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2024 --> Mar 2024
  • ||||||||||  Vasforda (bevacizumab biosimilar) / Hanwha Solutions, Prestige BioPharma, Huons, Intas
    Enrollment closed, Enrollment change, Metastases:  A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin (clinicaltrials.gov) -  Sep 15, 2023   
    P3,  N=650, Active, not recruiting, 
    In conclusion, Liztox injection proved to be a secure and efficacious intervention for managing upper extremity spasticity in post-stroke patients. Recruiting --> Active, not recruiting | N=500 --> 650
  • ||||||||||  Liztox (botulinum toxin type A) / Huons
    Trial completion:  To Evaluate HU-014 in the Treatment of Post Stroke Upper Limb (clinicaltrials.gov) -  Aug 1, 2023   
    P3,  N=198, Completed, 
    Recruiting --> Active, not recruiting | N=500 --> 650 Recruiting --> Completed
  • ||||||||||  Vasforda (bevacizumab biosimilar) / Hanwha Solutions, Prestige BioPharma, Huons, Intas
    Trial completion date, Trial primary completion date, Metastases:  A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin (clinicaltrials.gov) -  Jun 15, 2023   
    P3,  N=500, Recruiting, 
    Recruiting --> Completed Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Sep 2023 --> Dec 2023
  • ||||||||||  PBP1502 (adalimumab biosimilar) / Prestige BioPharma, Huons
    Trial completion date, Trial primary completion date:  To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects (clinicaltrials.gov) -  May 1, 2023   
    P1,  N=324, Recruiting, 
    Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Sep 2023 --> Dec 2023 Trial completion date: Aug 2023 --> Nov 2024 | Trial primary completion date: Mar 2023 --> Nov 2024
  • ||||||||||  PBP1502 (adalimumab biosimilar) / Prestige BioPharma, Huons
    Trial completion date, Trial primary completion date:  To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects (clinicaltrials.gov) -  Sep 28, 2022   
    P1,  N=324, Recruiting, 
    Trial completion date: Aug 2023 --> Nov 2024 | Trial primary completion date: Mar 2023 --> Nov 2024 Trial completion date: Dec 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Mar 2023
  • ||||||||||  Vasforda (bevacizumab biosimilar) / Hanwha Solutions, Prestige BioPharma, Huons, Intas
    Trial completion date, Trial primary completion date, Metastases:  A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin (clinicaltrials.gov) -  Jun 10, 2022   
    P3,  N=500, Recruiting, 
    Trial completion date: Dec 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Mar 2023 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: May 2022 --> Sep 2023
  • ||||||||||  Lipax (proliposomal intravesical paclitaxel) / TesoRx
    Journal:  AAV gene therapy for Tay-Sachs disease. (Pubmed Central) -  Apr 27, 2022   
    Patient TSD-001 was treated at 30 months with an equimolar mix of AAVrh8-HEXA and AAVrh8-HEXB administered intrathecally (i.t.), with 75% of the total dose (1 × 10 vector genomes (vg)) in the cisterna magna and 25% at the thoracolumbar junction...TSD-002 developed anticonvulsant-responsive seizures at 2 years of age. This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy.
  • ||||||||||  PBP1502 (adalimumab biosimilar) / Prestige BioPharma, Huons
    Enrollment open:  To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects (clinicaltrials.gov) -  Apr 10, 2022   
    P1,  N=324, Recruiting, 
    This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy. Not yet recruiting --> Recruiting
  • ||||||||||  Vasforda (bevacizumab biosimilar) / Hanwha Solutions, Prestige BioPharma, Huons, Intas
    Trial completion date, Trial primary completion date, Metastases:  A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin (clinicaltrials.gov) -  Sep 8, 2021   
    P3,  N=500, Recruiting, 
    (NCT03390673). Trial completion date: Nov 2021 --> Dec 2022 | Trial primary completion date: Aug 2021 --> May 2022
  • ||||||||||  Lipax (proliposomal intravesical paclitaxel) / TesoRx
    Enrollment closed, Trial completion date, Trial primary completion date:  Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer (clinicaltrials.gov) -  Sep 2, 2020   
    P1/2,  N=15, Active, not recruiting, 
    Persistence of paclitaxel in the voided urine at therapeutic concentrations up to 72 hours after instillation were observed. Recruiting --> Active, not recruiting | Trial completion date: May 2022 --> Aug 2022 | Trial primary completion date: May 2020 --> Aug 2020
  • ||||||||||  proliposomal intravesical paclitaxel (TSD-001) / TesoRx
    [VIRTUAL] PHASE 1 OUTCOMES OF A NOVEL THIRD GENERATION LIPOSOMAL PACLITAXEL FORMULATION (TSD-001) IN LOW-INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PATIENTS (WEWCC: 147B) -  May 17, 2020 - Abstract #AUA2020AUA_2483;    
    NMIBC patients exposed to escalating TSD-001 dose (10-540 mg paclitaxel) until maximum deliverable dose (540 mg) demonstrated no DLT.  Voiding function and bother were unchanged from baseline to completion.  There was no evidence of systemic paclitaxel exposure based on a valid bioanalytical assess.  No evidence of TCCa recurrence  has been observed at a mean follow-up of 12 months.  TSD-001 delivers high urinary concentrations of paclitaxel with no measurable systemic exposure, and is very well tolerated in NMIBC patients. Source of Funding: Lipac Oncology, LLC
  • ||||||||||  Vasforda (bevacizumab biosimilar) / Hanwha Solutions, Prestige BioPharma, Huons, Intas
    Trial completion date, Trial primary completion date, Metastases:  A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin (clinicaltrials.gov) -  Apr 15, 2020   
    P3,  N=500, Recruiting, 
    Research Funding: Private funding Trial completion date: Jun 2021 --> Nov 2021 | Trial primary completion date: May 2021 --> Aug 2021
  • ||||||||||  Vasforda (bevacizumab biosimilar) / Hanwha Solutions, Prestige BioPharma, Huons, Intas
    Enrollment open, Trial completion date, Trial primary completion date, Metastases:  A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin (clinicaltrials.gov) -  Nov 25, 2019   
    P3,  N=500, Recruiting, 
    Trial completion date: Jan 2022 --> May 2022 | Trial primary completion date: Jan 2020 --> May 2020 Not yet recruiting --> Recruiting | Trial completion date: Feb 2021 --> Jun 2021 | Trial primary completion date: Nov 2020 --> May 2021
  • ||||||||||  Vasforda (bevacizumab biosimilar) / Hanwha Solutions, Prestige BioPharma, Huons, Intas
    Trial completion:  To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin (clinicaltrials.gov) -  Jun 7, 2019   
    P1,  N=119, Completed, 
    Trial completion date: Jun 2019 --> Jan 2022 | Trial primary completion date: Jun 2019 --> Jan 2020 Recruiting --> Completed
  • ||||||||||  Lipax (proliposomal intravesical paclitaxel) / TesoRx
    Enrollment open, Trial completion date, Trial primary completion date:  Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer (clinicaltrials.gov) -  Apr 19, 2018   
    P1/2,  N=16, Enrolling by invitation, 
    Enrolling by invitation --> Recruiting Not yet recruiting --> Enrolling by invitation | Trial completion date: Sep 2018 --> Jun 2019 | Trial primary completion date: Aug 2018 --> Jun 2019
  • ||||||||||  Liztox (botulinum toxin type A) / Huons
    Trial completion:  The Safety and Efficacy Study of HU-014 Versus Botox (clinicaltrials.gov) -  Apr 12, 2018   
    P1/2,  N=57, Completed, 
    Recruiting --> Completed Recruiting --> Completed
  • ||||||||||  Vasforda (bevacizumab biosimilar) / Hanwha Solutions, Prestige BioPharma, Huons, Intas
    Trial completion date, Trial initiation date, Trial primary completion date:  To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin (clinicaltrials.gov) -  Apr 5, 2018   
    P1,  N=100, Not yet recruiting, 
    Recruiting --> Completed Trial completion date: Apr 2018 --> Nov 2018 | Initiation date: Jan 2018 --> Jun 2018 | Trial primary completion date: Apr 2018 --> Oct 2018
  • ||||||||||  Vasforda (bevacizumab biosimilar) / Hanwha Solutions, Prestige BioPharma, Huons, Intas
    Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin (clinicaltrials.gov) -  Apr 5, 2018   
    P3,  N=500, Not yet recruiting, 
    Trial completion date: Apr 2018 --> Nov 2018 | Initiation date: Jan 2018 --> Jun 2018 | Trial primary completion date: Apr 2018 --> Oct 2018 Trial completion date: Jun 2020 --> Feb 2021 | Initiation date: Jan 2018 --> Nov 2018 | Trial primary completion date: Jan 2020 --> Nov 2020
  • ||||||||||  Lipax (proliposomal intravesical paclitaxel) / TesoRx
    Trial initiation date, Trial primary completion date:  Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer (clinicaltrials.gov) -  Oct 12, 2017   
    P1/2,  N=16, Not yet recruiting, 
    Trial completion date: Jun 2020 --> Feb 2021 | Initiation date: Jan 2018 --> Nov 2018 | Trial primary completion date: Jan 2020 --> Nov 2020 Initiation date: Jun 2017 --> Dec 2017 | Trial primary completion date: Feb 2018 --> Aug 2018